Madrigal Pharmaceuticals, Inc. (MDGL)
MDGL moved a median of -0.18% 30 minutes after news, and -0.03% by the close. How MDGL actually reacts to news — the realized, point-in-time move the market made, measured across 129 labeled events over the last three years with zero look-ahead.
MDGL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.18% | 41% | 129 |
| 30-min | -0.18% | 44% | 129 |
| 60-min | -0.13% | 47% | 129 |
| to close | -0.03% | 50% | 129 |
| Middle 50% of MDGL reactions | -1.51% to +0.57% |
|---|---|
| Median reaction (30-min) | -0.18% |
| Measured reactions | 129 |
Half of all Madrigal Pharmaceuticals, Inc. news events land between -1.51% and +0.57% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MDGL reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 37 | -0.68% | 35% | -2.10% |
| Coverage initiations | 21 | +0.39% | 52% | -0.68% |
| Rating reiterations | 91 | -0.31% | 44% | -0.17% |
| Price-target raises | 30 | +0.15% | 57% | -0.48% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how MDGL ranks against every other measured name →
That’s how MDGL usually reacts — get an email when it moves on news →Email me when MDGL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MDGL's baseline. Nothing else.
Recent MDGL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.86% | -2.14% | |
| Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants | Press release | GlobeNewswire | -0.80% | -0.13% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.42% | -0.05% | |
| Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference | Press release | GlobeNewswire | +0.54% | +0.62% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.85% | -0.64% | |
| Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors | Press release | GlobeNewswire | -0.41% | +0.04% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.40% | -0.38% | |
| Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference | Press release | GlobeNewswire | +1.49% | -0.57% | |
| Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | -5.10% | -2.46% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.04% | -1.67% | |
| Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026 | Press release | GlobeNewswire | -0.32% | -0.74% | |
| Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio | Press release | GlobeNewswire | -0.55% | -0.57% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.45% | +1.94% | |
| Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH | Press release | PR Newswire | -0.75% | +2.75% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.17% | +0.01% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.03% | -1.52% | |
| Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 | Press release | GlobeNewswire | +1.13% | +8.33% | |
| Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH | Press release | GlobeNewswire | +0.26% | +0.64% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.05% | +0.83% | |
| Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk | Press release | GlobeNewswire | +0.40% | -1.01% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.00% | -4.67% | |
| Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | +3.20% | +1.61% | |
| Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline | Press release | GlobeNewswire | +0.29% | -3.04% | |
| Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026 | Press release | GlobeNewswire | -1.36% | -0.48% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.36% | -0.48% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.49% | +0.96% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.73% | -3.00% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.20% | +0.27% | |
| Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | -0.66% | +0.47% | |
| Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results | Press release | GlobeNewswire | -0.81% | -3.35% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.38% | +0.98% | |
| Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs | Press release | GlobeNewswire | -0.64% | -0.42% | |
| Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH | Press release | PR Newswire | -0.64% | -0.42% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.96% | +0.40% | |
| Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026 | Press release | GlobeNewswire | +0.28% | +1.37% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.94% | -3.39% | |
| Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.54% | +0.21% | |
| Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor | Press release | GlobeNewswire | -1.54% | -7.39% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.55% | +6.77% | |
| Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.18% | -0.04% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.07% | -1.38% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.43% | +0.94% | |
| Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences | Press release | GlobeNewswire | +1.90% | +5.41% | |
| Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis | Press release | GlobeNewswire | +1.40% | -0.43% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.67% | +0.25% | |
| Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | +3.85% | +9.46% | |
| Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025 | Press release | GlobeNewswire | -0.01% | -0.22% | |
| Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025 | Press release | GlobeNewswire | +0.26% | -2.49% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.26% | -2.49% | |
| Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | -1.61% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MDGL section they belong to.
Where else MDGL is measured.
MDGL earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| INNATE PHARMA (IPHYF) | 130 | 0.00% | 0% |
| Deciphera Pharmaceuticals, Inc. (DCPH) | 129 | +0.04% | 55% |
| Medicenna Therapeutics Corp (MDNA_TSE) | 127 | 0.00% | 46% |
| OPGEN INC (OPGN) | 127 | 0.00% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Madrigal Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled MDGL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 129 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of MDGL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MDGL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.